A Prospective, Multicenter, Phase II Clinical Trial of Vorolanib in Combination With Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Latest Information Update: 30 Jul 2024
At a glance
- Drugs Sintilimab (Primary) ; Vorolanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 30 Jul 2024 New trial record